Supplementary Figure 2 from Ultrasensitive Response Explains the Benefit of Combination Chemotherapy Despite Drug Antagonism

Supplemental Figure 2. Isobologram analysis shows antagonism between CH and HO in the CHOP regimen for Peripheral T-Cell Lymphoma. A) Left: shapes of equal-effect contour lines (isoboles) reveal non-additive drug interactions (Palmer et al.)9. Right: Cell viability is measured across an 11x11 concentration gradient to graph isobolograms. B) CH, HO, and CO drug interactions in four Peripheral T-Cell Lymphoma (PTCL) cell lines: KHYG-1, Ki-JK, MTA, SU-DHL-1 (n=4 replicates per plot). White contour lines highlight 50%, 20%, and 5% relative viability. Green dots mark a clinically relevant concentration, Csustained (the average plasma concentration in humans 6 hours after administration12). C) CH and HO pairwise drug interactions in three additional PTCL cell lines: SMZ-1, MOT-N1, DL-40 (n=4 replicates per plot).